Literature DB >> 16819941

Inducible Escherichia coli fermentation for increased plasmid DNA production.

Aaron E Carnes1, Clague P Hodgson, James A Williams.   

Abstract

Bacterial plasmids are the vectors of choice for DNA vaccines and short-term gene therapeutics. Growing plasmid DNA by microbial (Escherichia coli) fermentation is usually combined with alkaline lysis/chromatography methods of purification. To date, typical plasmid fermentation media and processes result in yields of 100-250 mg of plasmid DNA/l of culture medium, using standard high-copy pUC origin-containing plasmids. In order to address this initial and yield-limiting upstream step, we identified novel fermentation control parameters for fed-batch fermentation. The resulting fermentation strategies significantly increased specific plasmid yield with respect to cell mass while enhancing plasmid integrity and maintaining supercoiled DNA content. Fed-batch fermentation yield exceeding 1000 mg of plasmid DNA/l was obtained after reduction of plasmid-mediated metabolic burden during growth, and yields up to 1500 mg of plasmid DNA/l have been achieved with optimized plasmid backbones. Interestingly, by inducing high plasmid levels after sufficient biomass accumulation at low temperature and restricted growth, cells were able to tolerate significantly higher plasmid quantities than cells grown by conventional processes. This 5-10-fold increase in plasmid yield dramatically decreases plasmid manufacturing costs and improves the effectiveness of downstream purification by reducing the fraction of impurities.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16819941     DOI: 10.1042/BA20050223

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN: 0885-4513            Impact factor:   2.431


  13 in total

1.  DNA plasmid production in different host strains of Escherichia coli.

Authors:  Adam Singer; Mark A Eiteman; Elliot Altman
Journal:  J Ind Microbiol Biotechnol       Date:  2009-01-10       Impact factor: 3.346

2.  Critical design criteria for minimal antibiotic-free plasmid vectors necessary to combine robust RNA Pol II and Pol III-mediated eukaryotic expression with high bacterial production yields.

Authors:  Aaron E Carnes; Jeremy M Luke; Justin M Vincent; Sheryl Anderson; Angela Schukar; Clague P Hodgson; James A Williams
Journal:  J Gene Med       Date:  2010-10       Impact factor: 4.565

Review 3.  Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements.

Authors:  Chung-Jr Huang; Henry Lin; Xiaoming Yang
Journal:  J Ind Microbiol Biotechnol       Date:  2012-01-18       Impact factor: 3.346

Review 4.  Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production.

Authors:  James A Williams; Aaron E Carnes; Clague P Hodgson
Journal:  Biotechnol Adv       Date:  2009-02-20       Impact factor: 14.227

5.  Generic plasmid DNA production platform incorporating low metabolic burden seed-stock and fed-batch fermentation processes.

Authors:  James A Williams; Jeremy Luke; Sarah Langtry; Sheryl Anderson; Clague P Hodgson; Aaron E Carnes
Journal:  Biotechnol Bioeng       Date:  2009-08-15       Impact factor: 4.530

6.  Antibiotic-free production of a herpes simplex virus 2 DNA vaccine in a high yield cGMP process.

Authors:  Jared Nelson; Stephen Rodriguez; Neil Finlayson; Jim Williams; Aaron Carnes
Journal:  Hum Vaccin Immunother       Date:  2013-07-30       Impact factor: 3.452

7.  Improved antibiotic-free DNA vaccine vectors utilizing a novel RNA based plasmid selection system.

Authors:  Jeremy Luke; Aaron E Carnes; Clague P Hodgson; James A Williams
Journal:  Vaccine       Date:  2009-06-24       Impact factor: 3.641

8.  Engineering Escherichia coli to increase plasmid DNA production in high cell-density cultivations in batch mode.

Authors:  Gheorghe M Borja; Eugenio Meza Mora; Blanca Barrón; Guillermo Gosset; Octavio T Ramírez; Alvaro R Lara
Journal:  Microb Cell Fact       Date:  2012-09-19       Impact factor: 5.328

9.  Cultivation of E. coli carrying a plasmid-based Measles vaccine construct (4.2 kbp pcDNA3F) employing medium optimisation and pH-temperature induction techniques.

Authors:  Clarence M Ongkudon; Raelene Pickering; Diane Webster; Michael K Danquah
Journal:  Microb Cell Fact       Date:  2011-03-05       Impact factor: 5.328

10.  Factors affecting plasmid production in Escherichia coli from a resource allocation standpoint.

Authors:  Drew S Cunningham; Richard R Koepsel; Mohammad M Ataai; Michael M Domach
Journal:  Microb Cell Fact       Date:  2009-05-22       Impact factor: 5.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.